Associated Papers
The role of zongertinib, a highly selective tyrosine kinase inhibitor, in targeting HER2-mutant NSCLC: a bench-to-bedside review.
Heymach JV et al.
Expert Review of Anticancer Therapy, 2026
Genomic Profile of Non-Small Cell Lung Cancer in a Spanish Cohort: A 2-Year Descriptive Study Using Next-Generation Sequencing.
Carnero-Gregorio M et al.
Genes, 2026
ERBB2 I655V mutation correlates with efficacy of immunotherapy in gallbladder cancer.
Gao Q et al.
World Journal of Surgical Oncology, 2026
Hotspot mutations in HER2 interfaces destabilize structure, causing breast cancer treatment failure.
Dey P et al.
Oncogene, 2026
Common gene mutations in 103 authenticated colorectal cancer cell lines.
Kranjec C et al.
Oncogenesis, 2026
Sevabertinib, a Reversible HER2 Inhibitor with Activity in Lung Cancer.
Siegel F et al.
Cancer Discovery, 2026
Comparative Analysis of a Dual DNA-RNA Panel and a DNA-Only Panel for Sarcoma: Real-World Data From a Nationwide Genomic Database.
Nakata E et al.
Cancer Science, 2026
ERBB2 mutations promote recurrence and metastasis in non-muscle-invasive bladder cancer via HIF-1 phosphorylation: Insights from whole exome sequencing.
Wang X et al.
Journal of Pharmaceutical Analysis, 2026
Recurrent cancer-associated ERBB4 mutations are transforming and confer resistance to targeted therapies.
Ojala VK et al.
Molecular Oncology, 2025
Determinants of sensitivity to HER2-targeted antibody drug conjugates in urothelial cancer.
Chen Z et al.
Nature Communications, 2025
Concurrent genomic assessment of circulating tumour cells and ctDNA to guide therapy in metastatic breast cancer.
Allsopp RC et al.
Bmc Cancer, 2025
Comparative Performance of a Targeted Next-Generation Sequencing Assay Against Multiplexed Digital PCR Assays in Detecting ERBB2, ESR1, and PIK3CA Mutations in Plasma Circulating Cell-Free DNA from Liquid Biopsies.
Corné J et al.
The Journal of Molecular Diagnostics : Jmd, 2025
Genomic Profiling of Indian Gallbladder Carcinoma: Mutational Insights in a High-Incidence Population.
Suryavanshi M et al.
Jco Global Oncology, 2025
Genetic Aberrations in Normal Tissues Adjacent to Biliary Tract Cancers.
Kwon CH et al.
Biomedicines, 2025
Building a dynamic model for EGFR-family dimerization using quantitative, live-cell fluorescence methods.
Burns EA et al.
Biophysical Journal, 2025
Furmonertinib activity in NSCLC Harbouring EGFR L858R and ERBB2 S310F co-mutations: a case report with literature review.
Liu S et al.
Journal of Chemotherapy (florence, Italy), 2025
Clinical Outcomes, Genomic Heterogeneity, and Therapeutic Considerations Across Histologic Subtypes of Urothelial Carcinoma.
Chu CE et al.
European Urology, 2025
Determining the optimal approach to identify osimertinib resistance; the first line osimertinib cohort of the OSIRIS study.
van der Wel JWT et al.
Lung Cancer (amsterdam, Netherlands), 2025
Single-cell RNA profiling reveals an immunosuppressive microenvironment in EGFR double-mutant non-small cell lung cancer.
Yang J et al.
Translational Lung Cancer Research, 2025
Discriminating activating, deactivating and resistance variants in protein kinases.
Singh G et al.
Genome Medicine, 2025
Enhanced HER2 internalization by clathrin-dependent endocytosis in non-small cell lung cancer positive for HER2 mutations.
Shimauchi A et al.
British Journal of Cancer, 2025
Discovery of Novel RASGRF2 Fusions as a Therapeutic Target in Lung Adenocarcinoma of Never or Light Smokers.
Terashima Y et al.
Cancer Science, 2025
Prevalence of FOXA1 and ERBB2 activating mutations in extramammary Paget's disease: A retrospective multicenter analysis of 99 cases from Japanese and Taiwanese cohorts.
Omi M et al.
Journal of Dermatological Science, 2025
Chronic Liver Disease Associated Cholangiocarcinoma: Genomic Insights and Precision Therapeutic Strategies.
Oura K et al.
Cancers, 2025
Favourable Prognostic Significance of HER2 Mutations in Canine Pulmonary Adenocarcinoma Following Surgical Resection.
Ichimata M et al.
Veterinary and Comparative Oncology, 2025
ERBB2/HER2 Alterations in ctDNA and Metachronous Tissues of Patients with Metastatic Urothelial Cancer.
Vandekerkhove G et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2025
HER2 alterations across solid tumors: implications for comprehensive testing.
Ismail A et al.
The Oncologist, 2025
Profiling of HER2, KRAS, and PIK3CA mutations in uterine cervical neuroendocrine carcinoma and implications for oncogenic driver targeting therapy.
Chao WR et al.
Cancer Genetics, 2025
Integrative genomic and transcriptomic profiling reveals dysregulation of FOXA1-AGR2 axis in penoscrotal extramammary Paget's disease.
Zhang D et al.
Journal of Dermatological Science, 2025
Clinical utility of liquid biopsy next-generation sequencing for advanced non-small cell lung cancer in the Netherlands.
de Bitter TJJ et al.
Scientific Reports, 2025
Genomic Analyses Reveal the Evolving Characteristics of Intestinal Metaplasia and Gastric Cancer.
Xu X et al.
Cancer Research, 2025
MutationAssessor in cBioPortal.
Su Y et al.
Biorxiv : the Preprint Server for Biology, 2025
Mutational Landscape Assessed in Tumor Tissue and Circulating Tumor DNA During Treatment of Patients with HER2/ERBB2-Mutated Solid Tumors.
Egebjerg K et al.
Bmc Cancer, 2025
Comprehensive cross-sectional study of CIN prevalence, HPV genotyping, genetic alterations, and microbiota as molecular biomarkers for early cervical cancer detection: A pilot clinical study among women in Russia.
Romanishin A et al.
International Journal of Gynaecology and Obstetrics: the Official Organ of the International Federation of Gynaecology and Obstetrics, 2025
Genetic landscapes of breast tumors by next-generation sequencing with focus on less common types and genotype-phenotype correlations.
Hoda RS et al.
Human Pathology, 2025
A neomorphic protein interface catalyzes covalent inhibition of RASG12D aspartic acid in tumors.
Weller C et al.
Science (new York, N.y.), 2025
ctDNA Analysis in ERBB2-Amplified Colorectal Cancer: Biomarker Analysis of the MyPathway Trial.
Meric-Bernstam F et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2025
A targeted next-generation sequencing panel for identification of clinically relevant mutation profiles in solid tumours.
Das K et al.
Scientific Reports, 2025
Landscape of cancer associated EpCAM mutations: molecular modeling, predictive insights and impact on patient survival.
Dhotare PS et al.
Bmc Cancer, 2025
Penile Cancer Distant Metastasis or Primary Lung Cancer? Using Focused Genomic Profiling of Tumor and Germline Mutations With Next-Generation Sequencing for Clinical Decision-Making.
Moen CA et al.
Cancer Reports (hoboken, N.j.), 2025